Analyst Price Target is $26.33
▲ +98.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $26.33, with a high forecast of $27.00 and a low forecast of $26.00. The average price target represents a 98.89% upside from the last price of $13.24.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Biomea Fusion.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.